First-generation inhibitor midostaurin: Midostaurin is a multi-targeted kinase inhibitor that was the first FLT3 inhibitor approved by regulatory authorities for the treatment of FLT3-mutated AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.